Black Diamond Therapeutics

CompanyUnited States

Black Diamond Therapeutics develops one asset, in phase 2 (Silevertinib in non-small cell lung cancer with EGFR non-classical mutations). Mostly small molecule acting on EGFR; based in the United States.

1
Asset
Furthest stage
Phase 2
Raised
$134M
1
Trial
1
Signal

Pipeline

1
  • Silevertinib

    Inhibits mutant EGFR signaling to suppress tumor growth.

    Phase 2, Small molecule, EGFR, non-small cell lung cancer with EGFR non-classical mutations, non-small cell lung cancer (Clinical, no phase)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Funding rounds and grants3
  • Deals2
  • Signals1
  • Similar companies6

Intelligence